Key Facts at a Glance

• Drug: Elevidys (gene therapy for Duchenne muscular dystrophy)
• Developer: Sarepta Therapeutics
• Ex‑U.S. rights holder: Roche
• Current status:
  • Approved in 9 countries (including the U.S., with restrictions)
  • Rejected by the European Medicines Agency (EMA) in 2025
• New move: Roche will start a new global Phase 3 trial

Why Europe Said No Last Time

The EMA’s rejection in 2025 centered on insufficient clinical benefit, specifically:

• Trials did not show meaningful improvement in motor function
• The main biological effect (production of a shortened dystrophin protein) wasn’t clearly linked to clinical improvement
• Safety concerns were heightened after two patient deaths linked to the therapy in the U.S.

These issues made the existing data unsuitable for approval or reimbursement in Europe.

What’s Different About the New Trial?

Roche says it has worked closely with the EMA to redesign the study:

Trial Design Highlights

• Phase: Global Phase 3
• Patients: ~100 early ambulatory boys with Duchenne
• Randomization: Elevidys vs. placebo
• Duration: 72 weeks (longer than prior studies)
• Primary endpoint:
  • “Time to rise” from the floor
  • A well-established and clinically meaningful measure of disease progression in DMD

This is a notable shift from earlier studies that relied on endpoints regulators viewed as less convincing.

Why This Matters for Roche and Sarepta

For Roche

• Keeps hope alive for European and international approvals
• Could unlock reimbursement in markets where approval alone isn’t enough
• Signals long-term commitment despite prior regulatory failure

For Sarepta

• Validates Elevidys hasn’t been abandoned by its biggest partner
• But also confirms there’s no near-term path to Europe with existing data
• Commercial impact remains under pressure:
  • 2025 revenue: ~$900M
  • 2026 expectations: Analysts project well under $500M
  • Once‑anticipated multibillion‑dollar peak sales are no longer realistic

Timeline: This Is a Long Game

According to Wall Street analysts:

• Enrollment + follow-up: ~18 months
• Data readout: Likely 2028
• European resubmission: Only possible after positive results

So even in a best-case scenario, Elevidys is years away from a potential European comeback.

The Bigger Picture

Elevidys was a groundbreaking first-in-class gene therapy, but its story has become a cautionary tale about:

• Accelerated approvals based on limited data
• The gap between biological markers and real-world functional benefit
• The extremely high bar regulators apply to ultra-expensive gene therapies

Roche’s new trial doesn’t erase past problems, but it does offer a regulatory reset and one last serious attempt to prove clinical value.